VANCOUVER, BC, July 14, 2023 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical-stage natural psychedelic drug development company today announced a change of auditor from Crowe MacKay LLP (the “Former Auditor“) to MNP LLP (the “Successor Auditor“). At the request of the Company, the Former Auditor resigned as the auditor of the Company…

Source

Previous articleAlgernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement
Next articleCOMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology